Global Coronary Stents Market – Industry Trends - Forecast to 2026

  • Cardiovascular Devices
  • Upcoming Reports
  • Apr 2019
  • Global
  • 350 Pages
  • No of Tables: 60
  • No of Figures: 220

Global Coronary Stents Market By Type (Dual Therapy Stent, Bioresorbable Vascular Scaffold, Drug Eluting Stent (DES) (Paclitaxel, Limus-Based Drugs), Bio-Engineered Stent, Bare Metal Stent), Absorption Rate (Slow-Absorption DES, Fast-Absorption (DES)), Material (Stainless Steel, Cobalt Alloy Metal, Gold, Tantalum, Nitinol, Polymers), Rate (Slow-Absorption Stents, Fast-Absorption Stents), Application (Coronary Artery Disease, Peripheral Artery Disease), End-User (Hospitals, Cardiac Centers, Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) – Industry Trends & Forecast to 2026

Market Analysis: Global Coronary Stents Market

Global Coronary Stents Market is expected to rise from its initial estimated value of USD 7.76 billion in 2018 to an estimated value of USD 13.60 billion by 2026, registering a CAGR of 7.2% in the forecast period of 2019-2026.

Market Definition: Global Coronary Stents Market

A small mesh like elastic tube composed of metal like cobalt alloy or stainless steel that attaches onto small balloons and opens inside the artery to support the vessel wall and facilitates the blood flow is known as a Stent.

According to World Health Organization, there were an estimated 17.9 million people die which accounts for 31% of all deaths worldwide, almost more than half of these deaths could have been avoided with the availability of proper medical equipment and devices for healthcare procedures. This significant number is expected to act as a driver to the market growth.

Market Drivers

  • Increasing demand by supplier side and parent side due to convenience during medicine intake will drive the market.
  • Increase in diabetic population, increased consumption of alcohol, rising obese population, increase in hypertension, aging population are the main drivers of the market.

Market Restraints

  • Non-availability for the middle class people due to pricing of the stents is expected to act as a restraint to the market growth
  • Complications associated with implantation of stents is expected to act as a restraint to the market growth

Segmentation: Global Coronary Stents Market

  • By Product Type

    • Dual Therapy Stent
    • Bioresorbable Vascular Scaffold
    • Drug Eluting Stent (DES)

      • Paclitaxel
      • Limus-Based Drugs

    • Bio-Engineered Stent
    • Bare Metal Stent

  • By Absorption Rate

    • Slow-Absorption DES
    • Fast-Absorption DES

  • By Material

    • Stainless Steel
    • Cobalt Alloy Metal
    • Gold
    • Tantalum
    • Nitinol Polymers

  • By Rate

    • Slow-Absorption Stents
    • Fast-Absorption Stents

  • By Application

    • Coronary artery disease
    • Peripheral artery disease

  • By End-Users

    • Hospitals
    • Cardiac centers
    • Others

  • By Geography

    • North America

      • US.
      • Canada
      • Mexico

    • South America

      • Brazil
      • Argentina
      • Rest of South America

    • Europe

      • Germany
      • France
      • United Kingdom
      • Italy
      • Spain
      • Russia
      • Turkey
      • Belgium
      • Netherlands
      • Switzerland
      • Rest of Europe

    • Asia-Pacific

      • Japan
      • China
      • South Korea
      • India
      • Australia
      • Singapore
      • Thailand
      • Malaysia
      • Indonesia
      • Philippines
      • Rest of Asia Pacific

    • Middle East & Africa

      • South Africa
      • Egypt
      • Saudi Arabia
      • United Arab Emirates
      • Israel
      • Rest of Middle East & Africa

Key Developments in the Market:

  • On 6th January, 2017, Abbott has completed its $25 billion acquisition of St. Jude Medical, the healthcare company announced. The merger melds St. Jude’s strength in heart failure devices, catheters and defibrillators with St. Jude’s prowess in coronary intervention value repair. St. Jude bolstered its heart failure business a little over a year ago with the purchase of Thoratec for USD 3 billion.
  • In February 2017, PRO-Kinetic Energy Cobalt Chromium Bare-Metal Stent of Biotronik received FDA approval for treating coronary artery blockage. This novel medical device which has already been used to treat more than 650,000 patients worldwide.

Competitive Analysis: Global Coronary Stents Market

Global coronary stents market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of coronary stents market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Key Market Competitors: Global Coronary Stents Market

Few of the major competitors currently working in the coronary stents market are Abbott (US), Boston SciTech Inc. (US), Minvasys (France), Medinol Ltd (Israel), iVascular SLU (Spain), Elixir Medical Corporation (US), Inspire MD Inc. (Israel), STENTYS SA (France), Hexacath (France), Medtronic (US), Andramed GmbH (Germany), Cardinal Health (US), ORBUSNEICH MEDICAL (Hong Kong), Eurocor Tech GmbH (Germany), Comed B.V. (Netherlands), Endocor GmbH (Germany), MicroPort Scientific Corporation (China), Amaranth Medical, Inc. (Singapore), Terumo Corporation (Japan), Degania Silicone Ltd. (Israel), Meril Life Sciences Pvt. Ltd. (IN), InSitu Technologies Inc. (US), AlviMedica (Turkey), Biotronik SE & Co. KG (Germany), amg International GmbH (Ireland), Arthesys (France), Lepu Medical (China), Translumina Therapeutics (Germany), among other companies.

Research Methodology: Global Coronary Stents Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analysed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please Request an Analyst Call or can drop down your inquiry.

The key research methodology used by DBMR Research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Primary Respondents

Demand Side: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technological Writers, Scientists, Promoters, and Investors among others.

Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.

Reasons to Purchase this Report

  • Current and future of coronary stents market outlook in the developed and emerging markets
  • The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period
  • Regions/Countries that are expected to witness the fastest growth rates during the forecast period
  • The latest developments, market shares, and strategies that are employed by the major market players

Customization of the Report:

  • All segmentation provided above in this report is represented at country level
  • All products covered in the market, product volume and average selling prices will be included as customizable options which may incur no or minimal additional cost (depends on customization)

SKU-

1. INTRODUCTION

       1.1. OVERVIEW OF THE GLOBAL CORONARY STENTS MARKET
       1.2. MARKET SEGMENTATION & COVERAGE
                1.2.1. CURRENCY AND PRICING 
                1.2.2. LIMITATION
                1.2.3. STAKEHOLDERS

2. RESEARCH METHODOLOGY

       2.1. KEY TAKEAWAYS
       2.2. ARRIVING AT THE GLOBAL CORONARY STENTS MARKET SIZE
                2.2.1. MARKET CRACKDOWN APPROACH 
                2.2.2. COMPANY REVENUE AND MARKET SHARE ANALYSIS
                2.2.3. DATA TRIANGULATION
                2.2.4. KEY DATA POINTS FROM PRIMARY SOURCES
                2.2.5. KEY DATA POINTS FROM SECONDARY SOURCES
                2.2.6. PORTER’S FIVE FORCES MATRIX
       2.3. GLOBAL CORONARY STENTS MARKET: RESEARCH SNAPSHOT
       2.4. ASSUMPTIONS

3. MARKET LANDSCAPE SUMMARY

4. PREMIUM INSIGHTS

       4.1. OVERVIEW
       4.2. GLOBAL CORONARY STENTS MARKET: KEY PRIMARY INSIGHTS
       4.3. MARKET OVERVIEW
                4.3.1. DRIVERS
                4.3.2. RESTRAINTS
                4.3.3. OPPOTUNITIES
                4.3.4. THREATS
       4.4. KEY MARKET TRENDS AND UPCOMING TECHNOLOGIES

5. GLOBAL CORONARY STENTS MARKET, BY TYPE

       5.1. OVERVIEW
       5.2. DUAL THERAPY STENT
       5.3. BIORESORBABLE VASCULAR SCAFFOLD
       5.4. DRUG ELUTING STENT (DES)
                5.4.1. PACLITAXEL
                5.4.2. IMUS-BASED DRUGS
       5.5. BIO-ENGINEERED STENT
       5.6. BARE METAL STENT

6. GLOBAL CORONARY STENTS MARKET, BY ABSORPTION RATE

       6.1. SLOW-ABSORPTION DES
       6.2. FAST-ABSORPTION (DES)

7. GLOBAL CORONARY STENTS MARKET, BY MATERIAL

       7.1. OVERVIEW
       7.2. STAINLESS STEEL
       7.3. COBALT ALLOY METAL
       7.4. GOLD
       7.5. TANTALUM
       7.6. NITINOL
        7.7. POLYMERS

8. GLOBAL CORONARY STENTS MARKET, BY RATE

       8.1. OVERVIEW
       8.2. SLOW-ABSORPTION STENTS
       8.3. FAST-ABSORPTION STENTS

9. GLOBAL CORONARY STENTS MARKET, BY APPLICATION

       9.1. CORONARY ARTERY DISEASE
       9.2. PERIPHERAL ARTERY DISEASE

10. GLOBAL CORONARY STENTS MARKET, BY END USER

       10.1. HOSPITALS
       10.2. CARDIAC CENTERS
       10.3. OTHERS

11. GLOBAL CORONARY STENTS MARKET, BY GEOGRAPHY

       11.1. COUNTRYWISE CORONARY STENTS MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
                11.1.1. NORTH AMERICA
                            11.1.1.1. U.S.
                            11.1.1.2. CANADA
                            11.1.1.3. MEXICO
                11.1.2. EUROPE
                            11.1.2.1. GERMANY
                            11.1.2.2. FRANCE
                            11.1.2.3. U.K.
                            11.1.2.4. ITALY
                            11.1.2.5. SPAIN
                            11.1.2.6. RUSSIA
                            11.1.2.7. TURKEY
                            11.1.2.8. BELGIUM
                            11.1.2.9. NETHERLANDS
                            11.1.2.10. SWITZERLAND
                            11.1.2.11. REST OF EUROPE
                11.1.3. ASIA-PACIFIC (APAC)
                            11.1.3.1. JAPAN
                            11.1.3.2. CHINA
                            11.1.3.3. SOUTH KOREA
                            11.1.3.4. INDIA
                            11.1.3.5. AUSTRALIA
                            11.1.3.6. SINGAPORE
                            11.1.3.7. THAILAND
                            11.1.3.8. MALAYSIA
                            11.1.3.9. INDONESIA
                            11.1.3.10. PHILIPPINES
                            11.1.3.11. REST OF APAC
                11.1.4. SOUTH AMERICA
                            11.1.4.1. BRAZIL
                            11.1.4.2. REST OF SOUTH AMERICA
                11.1.5. MIDDLE EAST AND AFRICA
                            11.1.5.1. SOUTH AFRICA
                            11.1.5.2. REST OF MIDDLE EAST AND AFRICA
       11.2. KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES

12. GLOBAL CORONARY STENTS MARKET: COMPETITIVE LANDSCAPE

       12.1. GLOBAL CORONARY STENTS MARKET: COMPANY SHARE ANALYSIS
       12.2. U.S. CORONARY STENTS MARKET: COMPANY SHARE ANALYSIS
       12.3. EUROPE CORONARY STENTS MARKET: COMPANY SHARE ANALYSIS
       12.4. APAC CORONARY STENTS MARKET: COMPANY SHARE ANALYSIS
       12.5. SOUTH AMERICA CORONARY STENTS MARKET: COMPANY SHARE ANALYSIS
       12.6. MIDDLE EAST AND AFRICA CORONARY STENTS MARKET: COMPANY SHARE ANALYSIS
       12.7. MERGERS & ACQUISITIONS
       12.8. NEW PRODUCT DEVELOPMENT & APPROVALS
       12.9. EXPANSIONS
       12.10. REGULATORY CHANGES
       12.11. PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS            

13. GLOBAL CORONARY STENTS MARKET, COMPANY PROFILES

       13.1. ABBOTT VASCULAR
                13.1.1. OVERVIEW
                13.1.2. SWOT ANALYSIS
                13.1.3. PRODUCT PORTFOLIO
                13.1.4. REVENUE ANALYSIS
                13.1.5. ANALYSTS VIEW
       13.2. SCITECH
                13.2.1. OVERVIEW
                13.2.2. SWOT ANALYSIS
                13.2.3. PRODUCT PORTFOLIO
                13.2.4. REVENUE ANALYSIS
                13.2.5. ANALYSTS VIEW
       13.3. BOSTON SCIENTIFIC CORPORATION
                13.3.1. OVERVIEW
                13.3.2. SWOT ANALYSIS
                13.3.3. PRODUCT PORTFOLIO
                13.3.4. REVENUE ANALYSIS
                13.3.5. ANALYST VIEW
       13.4. MEDINOL LTD
                13.4.1. OVERVIEW
                13.4.2. SWOT ANALYSIS
                13.4.3. PRODUCT PORTFOLIO
                13.4.4. REVENUE ANALYSIS
                13.4.5. ANALYSTS VIEW
       13.5. IVASCULAR SLU
                13.5.1. OVERVIEW
                13.5.2. SWOT ANALYSIS
                13.5.3. PRODUCT PORTFOLIO
                13.5.4. REVENUE ANALYSIS
               13.5.5. ANALYSTS VIEW
       13.6. STENTYS SA
                13.6.1. OVERVIEW
                13.6.2. SWOT ANALYSIS
                13.6.3. PRODUCT PORTFOLIO
                13.6.4. REVENUE ANALYSIS
                13.6.5. ANALYSTS VIEW
       13.7. ELIXIR MEDICAL CORPORATION
                13.7.1. OVERVIEW
                13.7.2. SWOT ANALYSIS
                13.7.3. PRODUCT PORTFOLIO
                13.7.4. REVENUE ANALYSIS
                13.7.5. ANALYSTS VIEW
       13.8. INSPIRE MD
                13.8.1. OVERVIEW
                13.8.2. SWOT ANALYSIS
                13.8.3. PRODUCT PORTFOLIO
                13.8.4. REVENUE ANALYSIS
                13.8.5. ANALYSTS VIEW
       13.9. HEXACATH
                13.9.1. OVERVIEW
                13.9.2. SWOT ANALYSIS
                13.9.3. PRODUCT PORTFOLIO
                13.9.4. REVENUE ANALYSIS
                13.9.5. ANALYSTS VIEW
       13.10. MEDTRONIC
                13.10.1. OVERVIEW
                13.10.2. SWOT ANALYSIS
                13.10.3. PRODUCT PORTFOLIO
                13.10.4. REVENUE ANALYSIS
                13.10.5. ANALYSTS VIEW
       13.11. ORBUSNEICH
                13.11.1. OVERVIEW
                13.11.2. SWOT ANALYSIS
                13.11.3   PRODUCT PORTFOLIO
                13.11.4   REVENUE ANALYSIS
                13.11.5   ANALYSTS VIEW
       13.12. ANDRAMED GMBH
                13.12.1. OVERVIEW
                13.12.2. SWOT ANALYSIS
                13.12.3. PRODUCT PORTFOLIO
                13.12.4. REVENUE ANALYSIS
                13.12.5. ANALYSTS VIEW
       13.13. CORDIS CORPORATION
                13.13.1. OVERVIEW
                13.13.2. SWOT ANALYSIS
                13.13.3. PRODUCT PORTFOLIO
                13.13.4. REVENUE ANALYSIS
                13.13.5. ANALYSTS VIEW
       13.14. ENDOCOR GMBH
                13.14.1. OVERVIEW
                13.14.2. SWOT ANALYSIS
                13.14.3. PRODUCT PORTFOLIO
                13.14.4. REVENUE ANALYSIS
                13.14.5. ANALYSTS VIEW
       13.15. EUROCOR GMBH
                13.15.1. OVERVIEW
                13.15.2. SWOT ANALYSIS
                13.15.3. PRODUCT PORTFOLIO
                13.15.4. REVENUE ANALYSIS
                13.15.5. ANALYSTS VIEW
       13.16. COOK MEDICAL.
                13.16.1. OVERVIEW
                13.16.2. SWOT ANALYSIS
                13.16.3. PRODUCT PORTFOLIO
                13.16.4. REVENUE ANALYSIS
                13.16.5. ANALYSTS VIEW
       13.17. MICROPORT SCIENTIFIC CORPORATION
                13.17.1. OVERVIEW
                13.17.2. SWOT ANALYSIS
                13.17.3. PRODUCT PORTFOLIO
                13.17.4. REVENUE ANALYSIS
                13.17.5. ANALYSTS VIEW
       13.18. DEGANIA SILICONE LTD.
                13.18.1. OVERVIEW
                13.18.2. SWOT ANALYSIS
                13.18.3. PRODUCT PORTFOLIO
                13.18.4. REVENUE ANALYSIS
                13.18.5. ANALYSTS VIEW
       13.19. TERUMO CORPORATION
                13.19.1. OVERVIEW
                13.19.2. SWOT ANALYSIS
                13.19.3. PRODUCT PORTFOLIO
                13.19.4. REVENUE ANALYSIS
                13.19.5. ANALYSTS VIEW
       13.20. MERIL LIFE SCIENCES PVT. LTD.
                13.20.1. OVERVIEW
                13.20.2. SWOT ANALYSIS
                13.20.3. PRODUCT PORTFOLIO
                13.20.4. REVENUE ANALYSIS
                13.20.5. ANALYSTS VIEW
       13.21. ALVIMEDICA
                13.21.1. OVERVIEW
                13.21.2. SWOT ANALYSIS
                13.21.3. PRODUCT PORTFOLIO
                13.21.4. REVENUE ANALYSIS
                13.21.5. ANALYSTS VIEW
       13.22. ELIXIR MEDICAL CORPORATION
                13.22.1. OVERVIEW
                13.22.2. SWOT ANALYSIS
                13.22.3. PRODUCT PORTFOLIO
                13.22.4. REVENUE ANALYSIS
                13.22.5. ANALYSTS VIEW
       13.23. INSITU TECHNOLOGIES INC.
                13.23.1. OVERVIEW
                13.23.2. SWOT ANALYSIS
                13.23.3. PRODUCT PORTFOLIO
                13.23.4. REVENUE ANALYSIS
                13.23.5. ANALYSTS VIEW
       13.24. BIOTRONIK SE & CO. KG
                13.24.1. OVERVIEW
                13.24.2. SWOT ANALYSIS
                13.24.3. PRODUCT PORTFOLIO
                13.24.4. REVENUE ANALYSIS
                13.24.5. ANALYSTS VIEW
       13.25. AMG INTERNATIONAL GMBH
                13.25.1. OVERVIEW
                13.25.2. SWOT ANALYSIS
                13.25.3. PRODUCT PORTFOLIO
                13.25.4. REVENUE ANALYSIS
                13.25.5. ANALYSTS VIEW
       13.26. ARTHESYS
                13.26.1. OVERVIEW
                13.26.2. SWOT ANALYSIS
                13.26.3. PRODUCT PORTFOLIO
                13.26.4. REVENUE ANALYSIS
                13.26.5. ANALYSTS VIEW
       13.27. TRANSLUMINA GMBH
                13.27.1. OVERVIEW
                13.27.2. SWOT ANALYSIS
                13.27.3. PRODUCT PORTFOLIO
                13.27.4. REVENUE ANALYSIS
                13.27.5. ANALYSTS VIEW
       13.28. LEPU MEDICAL
                13.28.1. OVERVIEW
                13.28.2. SWOT ANALYSIS
                13.28.3. PRODUCT PORTFOLIO
                13.28.4. REVENUE ANALYSIS
                13.28.5. ANALYSTS VIEW
       13.29. ACCURA
                13.29.1. OVERVIEW
                13.29.2. SWOT ANALYSIS
                13.29.3. PRODUCT PORTFOLIO
                13.29.4. REVENUE ANALYSIS
                13.29.5. ANALYSTS VIEW
       13.30. CELONOVA BIOSCIENCES, INC.
                13.30.1. OVERVIEW
                13.30.2. SWOT ANALYSIS
                13.30.3. PRODUCT PORTFOLIO
                13.30.4. REVENUE ANALYSIS
                13.30.5. ANALYSTS VIEW
       13.31. MINVASYS
                13.31.1. OVERVIEW
                13.31.2. SWOT ANALYSIS
                13.31.3. PRODUCT PORTFOLIO
                13.31.4. REVENUE ANALYSIS
                13.31.5. ANALYSTS VIEW
       13.32. SVELTE MEDICAL
                13.32.1. OVERVIEW
                13.32.2. SWOT ANALYSIS
                13.32.3. PRODUCT PORTFOLIO
                13.32.4. REVENUE ANALYSIS
                13.32.5. ANALYSTS VIEW
       13.33. B. BRAUN MELSUNGEN AG
                13.33.1. OVERVIEW
                13.33.2. SWOT ANALYSIS
                13.33.3. PRODUCT PORTFOLIO
                13.33.4. REVENUE ANALYSIS
                13.33.5. ANALYSTS VIEW
       13.34. EUCATECH AG
                13.34.1. OVERVIEW
                13.34.2. SWOT ANALYSIS
                13.34.3. PRODUCT PORTFOLIO
                13.34.4. REVENUE ANALYSIS
                13.34.5. ANALYSTS VIEW

13. APPENDIX

14. ABOUT DATA BRIDGE MARKET RESEARCH

Please fill in the below form for detailed List of Table

Please fill in the below form for detailed List of Figure

Please fill in the below form for detailed Inquire Before Buying

Choose License Type
  • $5400.00
  • $4200.00
BUY NOW ADD TO CART